EP
PTCT icon

Eversept Partners’s PTC Therapeutics PTCT Stock Holding History

Eversept Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-48,600
Closed -$2.19M – 64
2019
Q2 		$2.19M Sell
48,600
-52,000
-52% -$2.05M 0.61% 35
2019
Q1 		$3.79M Buy
+100,600
New +$3.38M 1.1% 22

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Eversept Partners's PTCT Position: Q3 2019 in Review

Eversept Partners sold out of PTC Therapeutics (PTCT) in Q3 2019, closing a stake of 48,600 shares — an estimated $2.19M sold.

Eversept Partners first reported a position in PTCT in Q1 2019 and held it in 2 quarters. The position peaked at $3.79M in Q1 2019. 184 funds tracked by Wall St. Rank hold PTCT as of Q3 2019.

  • Eversept Partners reported no remaining PTC Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Eversept Partners sold 48,600 PTC Therapeutics shares in Q3 2019, an estimated $2.19M.
  • Eversept Partners first reported a position in PTC Therapeutics in Q1 2019 and held it in 2 quarters.
  • Eversept Partners's PTC Therapeutics position peaked at $3.79M in Q1 2019.
  • 184 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2019.

Based on Eversept Partners's 13F filing for Q3 2019, filed 13 Nov 2019.